Completed PHASE3 NCT00293514

TachoSil Versus Standard Surgical Treatment for Air Leakage in Pulmonary Lobectomy (TC-021-IM)

An Open, Randomised, Prospective, Multi-centre, Parallel-group Trial of TachoSil Versus Standard Surgical Treatment in Patients Undergoing Pulmonary Lobectomy for Lung Malignancy and Requiring Treatment for Air Leakage

Sponsor: Nycomed

Conditions Intraoperative Complications Pulmonary Diseases

Interventions Fibrinogen (human) + thrombin (human) (TachoSil)

Updated 5 times since 2017 Last updated: May 4, 2012 Started: Feb 28, 2006 Primary completion: Oct 31, 2007 Completion: Oct 31, 2007

This PHASE3 trial investigates Intraoperative Complications and Pulmonary Diseases and is currently completed. Nycomed leads this study, which shows 5 recorded versions since 2006 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Feb 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Nycomed

Data source: Nycomed

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Roskilde, Denmark